Testing TQB2101 for advanced blood cancers
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of blood cancer that has not responded to standard treatments or for which no good options are available.
- You must be in fairly good health (able to take care of yourself and be up and about).
- You must have at least one tumor or lymph node that can be seen on a CT scan (for example, a lymph node bigger than 1.5 cm).
- You must have adequate organ function, like blood counts, liver, and kidney function, within certain ranges (the study team will test these).
- You must not have had other cancers in the last 3 years, except for some very early or cured cancers like certain skin cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new drug called TQB6411 for people with lung cancer. It aims to see if the drug is safe and effective, and what side effects it might have.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
Hear when a new Advanced Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.